Programme Outline and Topics

Topics include:

  • Endocrinology of cardiovascular disease
  • Targeting the ACE2/Ang 1-7 axis of the RAAS
  • AT2 Receptors
  • Metabolic aspects of cardiovascular disease
  • Molecular mechanisms of hypertension
  • Therapeutic interventions targeting the RAAS (ARNI/Angiotensinogen siRNA)
  • Cardioprotection and interventions for heart failure
Provisional Programme
Wednesday, 28 November
15:00-15:10 Welcome   Ed Sturrock
Aldosteronism – Chairs: Jan  Danser and Muscha Steckelings
15:10-15:50 Genetics of primary aldosteronism and the new physiology of aldosterone production Maria Christina Zennaro (INSERM)
15:50-16:30 Endocrine Hypertension: Facts and Fictions Gian Paolo Rossi (University of Padova)
16:30-17:00 First inducible / reversible mouse model of primary aldosteronism Matthew Taylor (University of Michigan)
17:00-17:40 4 Selected talks from Abstracts
The effect of combination anti-hypertensive treatment on pulse wave velocity in Black Africans with mild to moderate hypertension Erika Jones (UCT)
Limited Contribution of Insulin Resistance to Obesity-Associated Increases in Ambulatory Blood Pressure in a Black African Community Adamu Bamaiyi  (WITS)
Nox5 Induces Vascular Dysfunction and Arterial Remodelling Independently of Blood Pressure Elevation in Ang II-Infused Nox5-Expressing Mice Karla Neves (University of Glasgow)
Kidney function and the renin-angiotensin-aldosterone system in young South Africans: The African-PREDICT study Lebo Gafane-Matemane (NWU)
18:00 Welcome Cocktail
Thursday, 29 November
 Cardio Protection and Interventions for Heart Failure – Chairs: Gian Paolo Rossi and Catherine Llorens-Cortes
08:30-09:10 Aortic reflected waves in risk determination Gavin Norton (University of Witwatersrand)
09:10-09:50 Aortic stiffness as a determinant of cardiovascular events beyond brachial and aortic blood pressure Angela Woodiwiss (University of Witwatersrand)
09:50-10:30 4 Selected talks from Abstracts
Genetics of rheumatic heart disease in Africans Babu Muhamed (UCT)
Establishing a unique chronic stress model to evaluate the risk for cardiovascular diseases onset Lukas Olivier (University of Stellenbosch)
On-Treatment Decreases in Aortic Pulse Pressure Induced by Antihypertensives Are Accounted for More by Reductions in Backward Than Forward Wave Pressures Vernice Peterson  (WITS)
Physical Activity Without Resistance Exercise Decreases Wave Reflection in Treated Refractory Hypertensives Daniel da Silva Fernandes  (WITS)
10:30-11:00 TEA
AT2-receptors – Chairs: Robson Santos and Sandrine Lecour
11:00-11:40 AT2-receptor agonists: The long way from identifying a new pharmacological target to first clinical studies in humans Muscha Steckelings (University of Southern Denmark)
11:40-12:20 Protective Effects of the Renin-Angiotensin System in the Brain: Stroke and Hypertension Colin Sumners (University of Florida)
12:20-12:30 2 Selected talks from Abstracts
Contribution of the retinoic acid receptor signalling to adrenal cortex morphology and functional zonation Rami El Zein (INSERM)
12:30-13:30 LUNCH
Profiling of the RAAS – Chairs: Stu Nicklin and Angela Woodiwiss
13:30-14:10 A detailed profile of the RAAS Fingerprint in young healthy black and white adults: The African-PREDICT study Alta Schutte (Northwest University)
14:10-14:50 RAAS-Triple A testing: Angiotensin based biomarkers in the personalized treatment of hypertension Marko Poglitsch (Attoquant Diagnostics)
14:50-15:30 Physiological treatment of resistant hypertension: importance of renin and aldosterone profile Brian Rayner (University of Cape Town)
15:30-15:40 Angiotensin peptides levels in professional cyclist after maximal incremental test Daisy Motta-Santos (UFMG)
15:45-16:15 TEA
From Alatensins to Ang 1-9 – Chairs: Maria Christina Zennaro and Marko Poglitsch
16:15-16:55 Going beyond the classic paradigm: alatensins Robson Santos (Federal University of Minas Gerais)
16:55-17:35 Ang-(1-7)/Mas and ET-1/ETBR- a new partnership Rhian Touyz (University of Glasgow)
17:35-18:15 Assessing angiotensin-(1-9) function in acute vascular injury and neointima formation Stuart Nicklin (University of Glasgow)
19:00 Conference dinner
Friday, 30 November
Therapeutic interventions targeting the RAAS – Chairs: Brian Rayner and Alta Schutte
08:30-09:10 Renin-angiotensin-aldosterone system inhibition: can we do better? Focus on ARNI and angiotensinogen suppression. Jan Danser (Erasmus MC)
09:10-09:50 Central-acting aminopeptidase A inhibitors for new treatment of hypertension and heart failure: from discovery to clinical trial Catherine Llorens-Cortes (INSERM)
09:50-10:30 Inhibition of ACE C-domain and neprilysin in a chronic angiotesnin II-dependent mouse model of hypertension Lauren Arendse (University of Cape Town)

Rheure Alves – Lopes (University of Glasgow)

10:30-11:00 TEA
11:00-11:30 Is moderate to chronic consumption of wine a way to target the RAAS for cardio protection? Sandrine Lecour (University of Cape Town)
Endocrinology and Immunology of the RAAS – Chairs:  Matthew Taylor and Colin Sumners
11:30-12:10 The novel nonapeptideacein targets angiotensin converting enzyme in the brain and induces dopamine release Jean Martinez (University of Montpellier)
12:10-12:50 Exploring links between perturbed immunometabolic pathways and risk for CVD onset in HIV-positive individuals Faadiel Essop (University of Stellenbosch)
12:50 Closing remarks Rhian Touyz and Ed Sturrock